New Launch24 Dec 2024, 01:42 pm
Biocon & Zentiva Receive DCP Approval for Liraglutide in European Union
AI Summary
Biocon Ltd. and its European partner, Zentiva, have announced a De-centralized Procedure (DCP) approval for their complex formulation, Liraglutide, in the European Union (EU). This approval covers the generic versions of Victoza® for Type-2 Diabetes treatment and Saxenda® for weight management. This is a significant step forward in Biocon's global expansion and commitment to providing high-quality, affordable healthcare solutions.
Key Highlights
- Biocon and Zentiva receive DCP approval for Liraglutide in the EU
- Approval covers generic versions of Victoza® for Type-2 Diabetes treatment
- Approval also includes Saxenda® for weight management
- Significant step in Biocon's global expansion
- Commitment to providing affordable healthcare solutions reaffirmed